Please assess the completion status of the following clinical trial:

Trial Title: Proprioception Testing in Persons With Sensorimotor Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic incomplete SCI, stroke or acquired brain injured ABI subjects.~* Able to tolerate sitting upright at for at least 1 hour.~* Significant, but not complete, motor deficit in the hand and wrist, as determined by the Study Physician performing the screening.~* Significant, but not complete somatosensory deficit in the hand and wrist as determined by the Study Physician performing the screening.~* Cognitively and behaviorally capable of complying with the regimen.~Exclusion Criteria:~* Fracture of the treated limb resulting in loss of range of motion.~* Progressive neurodegenerative disorder.~* DVT of the treated extremity.~* Uncontrolled seizure disorder.~* Uncontrolled high blood pressure/angina.~* Osteo- or rheumatoid arthritis limiting range of motion~* Contractures equal to or greater than 50% of the normal ROM.~* Chronic ITB therapy.~* Peripheral nerve injury of the treated extremity.~* Pain in affected limb or exercise intolerance.~* Participation in another therapy or activity-based program.~* Skin condition not tolerant of device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AMES Therapy and Diagnostic (Type: EXPERIMENTAL): During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).